title: Lack of protease inhibitor resistance following treatment failure--too good to be true?
abstract: A 29-year-old man with recently diagnosed HIV infection and a CD4 cell count of 225/mm³ began treatment with atazanavir (300 mg), ritonavir (100 mg), emtricitabine (200 mg), and tenofovir (300 mg) daily. For 18 months, he was treatment adherent and his plasma HIV RNA level was below the limit of detection. He then began a relationship with a new partner, who introduced him to methamphetamines. His medication adherence became erratic, and he missed appointments in clinic. Eventually. he was hospitalized for rehabilitation, and he resumed taking his medications on schedule. Following his discharge, he was found to have a plasma HIV RNA level of 11,400 copies/ml. Genotypic resistance testing revealed only an M184V mutation associated with emtricitabine resistance. A decision regarding his next treatment regimen needs to be made.
authors: Department of Medicine and the Duke Global Health Institute, Duke University Medical Center, Durham, North Carolina 27710, USA. jab5@duke.edu
authors: John A
authors: JA
authors: Bartlett
mesh_terms: D024882:Drug Resistance, Viral; D016333:HIV Protease / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans
chemical_list: D017320:HIV Protease Inhibitors; D016333:HIV Protease
references: J Clin Invest. 2013 Sep;123(9):3848-60
references: 23979165
references: Ann Intern Med. 2011 Apr 5;154(7):445-56
references: 21320923
references: Lancet. 2006 Aug 5;368(9534):476-82
references: 16890834
references: J Infect Dis. 2004 Jan 1;189(1):51-60
references: 14702153
references: J Acquir Immune Defic Syndr. 2006 Mar;41(3):323-31
references: 16540933
references: J Virol. 2001 Jan;75(2):589-94
references: 11134271
references: N Engl J Med. 2008 May 15;358(20):2095-106
references: 18480202